COTY heads into today's earnings carrying a 25% one-month rally — yet the stock still trades at $2.56, pinned between analysts who can't agree by a factor of four on what it's worth.
Options traders are actually leaning bullish into the number, not defensive. The put/call ratio has slipped to 0.31 — marginally below its 20-day average of 0.33, and nowhere near the fearful end of its 52-week range of 0.16 to 0.69. That's a modest call-side tilt. It doesn't signal conviction, but it does confirm the options market is not bracing for a collapse.
Short sellers have been retreating. Short interest as a percentage of free float has fallen from around 4.4% in mid-April to 3.5% today — a 19% decline over the past month. That unwinding aligns with the stock's sharp rebound. Borrow conditions confirm there's no squeeze at work here: the cost to borrow has eased to just 0.43%, down roughly 13% on the week, and availability in the lending market remains generous. Short sellers are leaving, but they're leaving on their own terms.
The analyst debate around Coty is unusually wide and has sharpened in recent weeks. RBC's Nik Modi reiterated his Outperform rating on May 4, maintaining an $8.00 target — more than three times the current price. That sits in stark contrast to Barclays, which cut its target to $2.00 in April while keeping an Underweight, and Deutsche Bank, which lowered to $2.00 in late March on a Hold. The mean consensus target is $3.09 — still a 21% implied upside — but the dispersion tells the real story. Bears point to a structurally challenged setup: no meaningful presence in fast-growing skincare, limited e-commerce scale, exposure to a promotional-heavy mass market, and a leadership transition still in flux. Bulls counter with a clean-beauty repositioning narrative and a valuation that, on EV/EBITDA of 7.7x and a price-to-book of 0.57x, already prices in a lot of bad news.
The earnings print will test whether Coty's operational reality — margins, volume trends in its core fragrance and mass cosmetics franchises, and any update on strategic direction from its interim CEO — supports even the modest recovery the stock has started to price back in. The last time the company reported, in February, the stock fell 19% on the day. That reaction is not a forecast; it is the bar the market will measure today's print against.
See the live data behind this article on ORTEX.
Open COTY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
